{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:08:51Z","timestamp":1794935331463,"version":"4.9.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06844-1","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:53:18Z","timestamp":1772067198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The impact of venetoclax treatment duration on efficacy and hematologic toxicity in acute myeloid leukemia: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"105","author":[{"given":"Ying","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihan","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunying","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianshan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"6844_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"issue":"Supplement","key":"6844_CR2","doi-asserted-by":"publisher","first-page":"e19008","DOI":"10.1200\/JCO.2021.39.15_suppl.e19008","volume":"39","author":"D Blanding","year":"2021","unstructured":"Blanding D, Jonathan BK, Rangel CA et al (2021) Response rates in acute myeloid leukemia patients treated with attenuated durations of venetoclax in combination with hypomethylating agents. J Clin Oncol 39(Supplement):e19008. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.e19008","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"6844_CR3","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1182\/blood-2024-200013","volume":"144","author":"M Kanaya","year":"2024","unstructured":"Kanaya M, Onozawa M, Matsukawa T et al (2024) Evaluation of Venetoclax duration in Venetoclax-azacitidine regimen for untreated acute myeloid leukemia: real world experience from Hokkaido leukemia net. Blood 144(Supplement 1):6063. https:\/\/doi.org\/10.1182\/blood-2024-200013","journal-title":"Blood"},{"issue":"1","key":"6844_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41408-025-01269-x","volume":"15","author":"C Willekens","year":"2025","unstructured":"Willekens C, Bazinet A, Chraibi S et al (2025) Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. Blood Cancer J 15(1):68. https:\/\/doi.org\/10.1038\/s41408-025-01269-x","journal-title":"Blood Cancer J"},{"issue":"9","key":"6844_CR5","doi-asserted-by":"publisher","first-page":"16027","DOI":"10.18632\/oncotarget.13784","volume":"8","author":"L Hu","year":"2017","unstructured":"Hu L, Li M, Ding Y et al (2017) Prognostic value of RDW in cancers: a systematic review and meta-analysis. Oncotarget 8(9):16027\u201316035","journal-title":"Oncotarget"},{"issue":"3","key":"6844_CR6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","volume":"102","author":"M Aiba","year":"2023","unstructured":"Aiba M, Shigematsu A, Suzuki T et al (2023) Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia. Ann Hematol 102(3):541\u2013546. https:\/\/doi.org\/10.1007\/s00277-023-05102-y","journal-title":"Ann Hematol"},{"issue":"2","key":"6844_CR7","doi-asserted-by":"publisher","first-page":"E63","DOI":"10.1002\/ajh.27180","volume":"99","author":"O Karrar","year":"2024","unstructured":"Karrar O, Abdelmagid M, Rana M et al (2024) Venetoclax duration (14 vs. 21 vs. 28\u2009days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: comparative analysis of response, toxicity, and survival. Am J Hematol 99(2):E63\u2013E66. https:\/\/doi.org\/10.1002\/ajh.27180","journal-title":"Am J Hematol"},{"issue":"7","key":"6844_CR8","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.3390\/cancers17071138","volume":"17","author":"A Sch\u00fcpbach","year":"2025","unstructured":"Sch\u00fcpbach A, Akhoundova D, Bacher U et al (2025) Impact of venetoclax treatment schedule on hematologic recovery and treatment response in AML patients unfit for intensive chemotherapy. Cancers (Basel) 17(7):1138. https:\/\/doi.org\/10.3390\/cancers17071138","journal-title":"Cancers (Basel)"},{"key":"6844_CR9","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L et al (2016) Genomic classifification and prognosis in acute myeloid leukemia. N Engl J Med 374:2209\u20132221","journal-title":"N Engl J Med"},{"key":"6844_CR10","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V et al (2024) Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol 99:615\u2013624","journal-title":"Am J Hematol"},{"key":"6844_CR11","first-page":"2293512","volume":"29","author":"J Cui","year":"2024","unstructured":"Cui J, Chen X, Li C et al (2024) Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia. Am J Hematol 29:2293512","journal-title":"Am J Hematol"},{"issue":"1","key":"6844_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41408-025-01324-7","volume":"15","author":"M Kanaya","year":"2025","unstructured":"Kanaya M, Onozawa M, Matsukawa T et al (2025) Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net. Blood Cancer J 15(1):118. https:\/\/doi.org\/10.1038\/s41408-025-01324-7","journal-title":"Blood Cancer J"},{"key":"6844_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/FTD.0000000000001151","volume":"46","author":"M Philippe","year":"2024","unstructured":"Philippe M, Guitton J, Goutelle S et al (2024) Pharmacokinetic consideration of venetoclax in acute myeloid leukemia patients: a potential candidate for TDM? A short communication. Ther Drug Monit 46:127\u2013131. https:\/\/doi.org\/10.1097\/FTD.0000000000001151","journal-title":"Ther Drug Monit"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06844-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06844-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06844-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:58:34Z","timestamp":1776405514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06844-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6844"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06844-1","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"139"}}